ArticleOncotarget2019

Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia.

Stacey J Baker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.